1 |
Bosch FX, Lorincz A, Munoz N, Meijier CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65
DOI
ScienceOn
|
2 |
Lazcano-Ponce E, Herrero R, MuDoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-20
DOI
ScienceOn
|
3 |
Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002;87:324-33
DOI
ScienceOn
|
4 |
Woodman CB, Collins S, Winter H, et al. Natural history of cervical papillomavirus infection in young women: a longitudinal cohort study. Lancet 2002;357: 1831-6
DOI
ScienceOn
|
5 |
de Gruijl TD, Bontkes HJ, Walboomers JMM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:630-8
DOI
ScienceOn
|
6 |
Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1977;102:3-8
|
7 |
Rosendaal L, Walboomers JMM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomor-phologically normal cervical smears. Int J Cancer 1996;68:766-9
DOI
ScienceOn
|
8 |
Evans TG, Bonnez W, Rose RC, et al. Phase I study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001;183:1485-93
DOI
ScienceOn
|
9 |
Bosch FX, Rohan T, Schneider A, et al. Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference. J Clin Pathol 2001;54:163-75
DOI
ScienceOn
|
10 |
Jacobs MV, Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific diffe-rentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbial 1995;33:901-5
|
11 |
Stoler MH. Advances in cervical screening technology. Mod Pathol 2000;13:275-84
DOI
ScienceOn
|
12 |
Kulasingam SK, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. Comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57
DOI
ScienceOn
|
13 |
Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particles vaccine. J Natl Cancer Inst 2001;93:284-92
DOI
ScienceOn
|
14 |
Schlecht NF. Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intrae-pithelial neoplasia. JAMA 2002;286:3106-14
DOI
ScienceOn
|
15 |
Shin HR, Lee DH. Cancer incidence in Busan, Korea, 1996-1997. Busan: Association of Busan Cancer Registry, 2000
|
16 |
Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73
DOI
ScienceOn
|
17 |
Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002;95:2145-51
DOI
ScienceOn
|
18 |
Sukvirach S, Smith JS, Kesararat W, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. 19th International Papillomavirus Conference 2001;P-243:149
|
19 |
Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2002;87:221-7
|
20 |
Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8
DOI
ScienceOn
|
21 |
Pham TH, Nguyen TH, Herrero R, et al. Human papillomavirus infection among women in South and North Vietnam. Br J Cancer 2003;104:213-20
|
22 |
Combita AL, Bravo MM, Touze A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 viruslike particles in Colombian women with invasive cervical cancer. Int J Cancer 2002;97:796-803
DOI
ScienceOn
|
23 |
Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74
DOI
ScienceOn
|
24 |
Touze A, de Sanjose S, Coursaget P, et al. Prevalence of anti-human rapillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbial 2001;39:4344-8
DOI
ScienceOn
|
25 |
Carer JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody response following incident infection. J Infect Dis 2000;181:1911-9
DOI
ScienceOn
|
26 |
Hwang T. Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean women. J Korean Med Sci 1999;14:593-9
DOI
PUBMED
|